Inflammation in Alzheimer's disease: insights from immunotherapy.

More than 20 years after its initial formulation, the amyloid cascade hypothesis—which postulates that build-up of toxic amyloid-β species initiates a series of events that culminates in neurodegeneration and symptoms (Hardy and Higgins, 1992)—continues to dominate thinking on the pathogenesis of Alzheimer’s disease. Although the exact sequence of events linking amyloid-β accumulation to aggregation of hyperphosphorylated tau in different neuronal compartments, neuronal loss, synaptic dysfunction and symptoms remains unknown, there is now a substantial body of evidence implicating neuroinflammation in the pathogenesis of Alzheimer’s disease. Thus activated microglia accumulate around amyloid plaques both in the brains of individuals with Alzheimer’s disease and in transgenic mice, and have been implicated in promoting neurodegeneration (Akiyama et al. , 2000). Imaging studies using the 11C- R -PK11195 PET ligand provide evidence that activated microglial accumulate in the vicinity of amyloid plaque pathology, and that activated microglial burden correlates with declining cognition (Edison et al. , 2008). Genome-wide association studies have identified a number of risk variants for Alzheimer’s disease implicated in inflammatory responses (Bettens et al. , 2013); exome sequencing has revealed polymorphisms in the microglial receptor TREM2 gene as a rare but significant risk for Alzheimer’s disease (Guerreiro et al. , 2013; Jonsson et al. , 2013); and recently, the CD33 risk allele has been shown to inhibit microglial clearance of amyloid-β (Bradshaw et al. , 2013; Griciuc et al. , 2013). Finally, an integrative network-based genetic analysis of Alzheimer’s disease brain has implicated disturbance in immune/microglial networks in the pathogenesis of the disease (Zhang et al. , 2013). If inflammation, and microglial activation in particular, are core features of Alzheimer’s disease, the exact mechanisms involved, and the roles of the different inflammatory components are far less clear. Microglia—the predominant macrophage species within the brain—can express different cell-surface …

[1]  J. Trojanowski,et al.  Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. , 2013, Brain : a journal of neurology.

[2]  C. Holmes,et al.  Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. , 2013, Brain : a journal of neurology.

[3]  Nathan D. Kingery,et al.  Scara1 deficiency impairs clearance of soluble Amyloid-β by mononuclear phagocytes and accelerates Alzheimer’s-like disease progression , 2013, Nature Communications.

[4]  Keith A. Johnson,et al.  CD33 Alzheimer’s disease locus: Altered monocyte function and amyloid biology , 2013, Nature Neuroscience.

[5]  Bradley T. Hyman,et al.  Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta , 2013, Neuron.

[6]  G. Mead,et al.  Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia , 2013, Alzheimer's & Dementia.

[7]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[8]  Joshua H. K. Tam,et al.  A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection. , 2013, Contrast media & molecular imaging.

[9]  Christine Van Broeckhoven,et al.  Genetic insights in Alzheimer's disease , 2013, The Lancet Neurology.

[10]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[11]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[12]  E. Karran Current status of vaccination therapies in Alzheimer's disease , 2012, Journal of neurochemistry.

[13]  K. Blennow,et al.  Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[14]  Keith A. Johnson,et al.  THE A4 TRIAL: ANTI-AMYLOID TREATMENT OF ASYMPTOMATIC ALZHEIMER'S DISEASE , 2012, Alzheimer's & Dementia.

[15]  E. Planel,et al.  Is general anaesthesia a risk factor for Alzheimer's? Clues from biomarkers , 2012, Alzheimer's & Dementia.

[16]  N. Tabet,et al.  Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. , 2012, The Cochrane database of systematic reviews.

[17]  B. Zlokovic Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[18]  H. Paulson,et al.  Genetics of Dementia , 2011, Seminars in neurology.

[19]  Clifford R. Jack,et al.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.

[20]  D. Wald,et al.  Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participants , 2011, Alzheimer's & Dementia.

[21]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[22]  C. Holmes,et al.  Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease , 2010, Acta Neuropathologica.

[23]  V. Perry,et al.  Microglia in neurodegenerative disease , 2010, Nature Reviews Neurology.

[24]  Martin Rossor,et al.  Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study , 2008, Neurobiology of Disease.

[25]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[26]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[27]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[28]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[29]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[30]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[31]  J. Loike,et al.  Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils , 1996, Nature.

[32]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[33]  J. Winn,et al.  Brain , 1878, The Lancet.

[34]  Kewei Chen,et al.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.

[35]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[36]  J. Loike,et al.  Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. , 1996, Nature.